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Introduction: We previously demonstrated that a single-chain fragment variable (scFv) specific to collagen type II (CII)
posttranslationally modified by reactive oxygen species (ROS) can be used to target anti-inflammatory therapeutics
specifically to inflamed arthritic joints. The objective of the present study was to demonstrate the superior efficacy of
anti-inflammatory cytokines when targeted to inflamed arthritic joints by the anti-ROS modified CII (anti-ROS-CII) scFv in
a mouse model of arthritis.
Methods: Viral interleukin-10 (vIL-10) was fused to anti-ROS-CII scFv (1-11E) with a matrix-metalloproteinase (MMP)
cleavable linker to create 1-11E/vIL-10 fusion. Binding of 1-11E/vIL-10 to ROS-CII was determined by enzyme-linked
immunosorbent assay (ELISA), Western blotting, and immune-staining of arthritic cartilage, whereas vIL-10 bioactivity
was evaluated in vitro by using an MC-9 cell-proliferation assay. Specific in vivo localization and therapeutic efficacy
of 1-11E/vIL-10 was tested in the mouse model of antigen-induced arthritis.
Results: 1-11E/vIL-10 bound specifically to ROS-CII and to damaged arthritic cartilage. Interestingly, the in vitro
vIL-10 activity in the fusion protein was observed only after cleavage with MMP-1. When systemically administered
to arthritic mice, 1-11E/vIL-10 localized specifically to the arthritic knee, with peak accumulation observed after 3
days. Moreover, 1-11E/vIL-10 reduced inflammation significantly quicker than vIL-10 fused to the control anti-hen
egg lysozyme scFv (C7/vIL10).
Conclusions: Targeted delivery of anti-inflammatory cytokines potentiates their anti-arthritic action in a mouse
model of arthritis. Our results further support the hypothesis that targeting biotherapeutics to arthritic joints may
be extended to include anti-inflammatory cytokines that lack efficacy when administered systemically.Introduction
The hallmark of rheumatoid arthritis (RA) is chronic syn-
ovial inflammation that results in progressive joint damage.
The pathogenesis of the disease is characterized by auto-
immunity, chronic inflammatory synovitis, and destruction
of the cartilage and the adjacent joint tissues [1]. These
pathogenic processes are due to an imbalance in the cyto-
kine network, where pro-inflammatory cytokines, such
as tumor necrosis factor (TNF)-α, IL-1β, and IL-6 are over-
expressed in the RA joint [2]. Homeostatic regulatory* Correspondence: a.nissim@qmul.ac.uk
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stated.mechanisms in turn result in increased production of anti-
inflammatory cytokines, such as IL-10 and transforming
growth factor (TGF)-β, but this is not sufficient to counter
the pro-inflammatory cytokines produced [3].
With this in mind, two alternative therapeutic ap-
proaches have been investigated. One is to neutralize the
pro-inflammatory cytokines, and the other is to increase
the concentration of the anti-inflammatory cytokines. Sys-
temic treatment with TNF-α-blocking reagents is now a
standard treatment of patients with RA failing to respond
to conventional disease-modifying anti-rheumatic drugs
(DMARDs) [4]. However, increasing evidence suggests
that inhibition of TNF-α is associated with increased risk
of infections due to general immune-suppression [5,6].
Moreover, despite the established clinical efficacy of anti-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Hughes et al. Arthritis Research & Therapy 2014, 16:R151 Page 2 of 11
http://arthritis-research.com/content/16/4/R151TNF-α, a subset of patients (30% to 40%) does not re-
spond or has a suboptimal clinical response to anti-TNF-α
treatment [7].
Our hypothesis is that targeting of biologic drugs to the
inflamed joint will result in high local concentrations and
low systemic concentrations, increasing efficacy while
minimizing side effects. Additionally, a lower total dose
may be effective, thereby reducing the cost of treatment.
Targeting could be achieved by the identification of an in-
flamed joint tissue specific marker. We hypothesized that
the influx of infiltrating leukocytes consumes increased
amounts of oxygen and thereby generates high levels of
ROS [8]. In turn, the influx of ROS results in chemical
posttranslational modification of major specific cartilage
components such as CII, resulting in formation of ROS-
CII. ROS-CII would therefore be present in inflamed
joints, but not in healthy joints, and thus represents an in-
flamed joint-specific target. Targeting may therefore be
achieved by an ROS-CII-specific antibody.
By using a phage display human antibody library, we have
developed a panel of human single-chain fragment variable
(scFv) that binds specifically to ROS-CII [9]. One of these
clones, 1-11E, localizes specifically in arthritic joints of
mice. Hence, 1-11E fused to the murine tumor necrosis fac-
tor receptor 2-Fc-fusion protein (mTNFR2-Fc), which
would scavenge pro-inflammatory TNF-α, had an enhanced
therapeutic effect on inflamed knee swelling compared with
mTNFR2-Fc fused to the nonrelevant anti-hen egg lyso-
zyme (HEL) scFv, (C7/mTNFR2-Fc), or mTNFR2-Fc alone.
The current study is built on the previous study with 1-
11E/mTNFR2-Fc to extend the range of targeted thera-
peutics to include an anti-inflammatory cytokine, IL-10.
IL-10 is a major anti-inflammatory cytokine that inhibits
the production of Th1 cytokines, such as interferon-γ,
Th17 cytokines, and IL-17 [10], while increasing produc-
tion of IL-1R, soluble TNF receptors, and enhanced re-
lease of Th2 cytokines. IL-10 also blocks NF-κB activity in
macrophages, decreasing the expression of major histo-
compatibility complex class II and co-stimulatory mole-
cules, and the production of TNF-α, IL-6, and IL-1 [11].
Systemic treatment of mice with collagen-induced arthritis
(CIA) with recombinant IL-10 was efficacious, whereas
anti-IL-10 antibodies exacerbated disease [12]. Viral IL-10
(vIL-10) has attracted attention for therapy, as it lacks some
immunostimulatory effects of IL-10, while retaining all of
the immunosuppressive actions of human IL-10 (hIL-10)
[13]. Indeed, native and vIL-10 on rabbit antigen–induced
arthritis (AIA) demonstrated equal efficacy [14].
Interestingly, gene therapy for CIA with adenoviral vec-
tors encoding vIL-10 had a negligible effect when adminis-
tered systemically, but significantly reduced disease when
delivered intra-articularly [15]. Unfortunately, trials of
IL-10 in RA were disappointing [16]. Efficacy might be
increased if IL-10 were delivered locally. However, due tothe number and inaccessibility of many affected joints in
RA, direct injection of proteins or gene therapy vectors is
not a feasible option.
A step toward targeting IL-10 to arthritic joints was re-
ported by Trachsel and Schwarger et al. [17,18]. They
fused human monoclonal antibodies specific to markers of
angiogenesis (L19) to IL-10, IL-2, or TNF-α. Although
L19/IL-2 and L19/TNF-α treatment led to increased arth-
ritic scores and paw swelling, the L19/IL-10 fusion protein
displayed therapeutic efficacy, which was superior to the
activity of IL-10 fused to an antibody of irrelevant specifi-
city in the CIA mouse. This work, however, targets IL-10
to an angiogenic marker, which is not exclusive to the
damaged joint tissue.
In this study, we describe the development of 1-11E/
vIL-10 fusion protein and the improved therapeutic effi-
cacy of IL-10 in mice with antigen-induced arthritis when
targeted to arthritic joints by anti-ROS-CII scFv, 1-11E.
Methods
Expression of 1-11E/vIL-10 fusion
The 1-11E/vIL-10 fusion was cloned into pcDNA6 vector
(Invitrogen, Paisley, UK). vIL-10 was PCR with the follow-
ing primers: Forward: 5′-AAAGCGGCCG CAGGGGGAG
GCGGATCCCCGCTCGGGCTTTGGGCGGGAGGGGG
CTCACAATGT GACAATTTTCCC-3′ and reverse: 5′
TTTTGCGGCCGCCCTGGCTTTAATTGTCAT-3′. This
resulted in vIL-10 omitted from its signal peptide at the
5′ end and replaced with the MMP cleavage site
(PLGLWA) flanked by Gly4Ser1 linker from both sides
(Figure 1A). After cloning IL-10 into the NotI and SacII
restriction sites, the scFv was amplified to contain the
TNFR2 signal peptide (MAPAALWVALVFELQLWAT
GHT): forward: 5′-ATATATAAGCTT ATGGCGCCC
GCCGCCCTCTGGGTCGCGCTGGTCTTCGAACTGC
AGCTGTGGGCCACCGGGCACACATCTAGAATGGC
CGAGGTGCAGCTG-3′, and reverse: 5′-ATATATGC
GGCCGCCCGTTTGATTTCCACCTT-3′ and cloned into
the HindIII and NotI. Similarly, hen egg lysozyme-specific
scFv, C7, was cloned as fusion to vIL-10 (C7/vIL10) as non-
relevant scFv for negative control.
We performed transient transfections by using adherent
HEK-293 cells using FuGENE 6 and according to manu-
facturer’s instructions (Promega UK, Southampton, UK).
Culture medium was harvested after 3 days, and fusion
protein was purified by using a nickel chelate column
(QIAGEN, Crawley, UK) and following the manufacturer’s
instructions.
Evaluation of the molecular integrity of the fusion protein
Fusion protein was separated on SDS-PAGE under de-
naturing conditions after purification with Ni-NTA Agar-
ose (Qiagen, Crawley, UK) or after overnight digestion of
1-11E/vIL-10 fusion by the catalytic domains of MMP-1,
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Figure 1 Design and characterization of 1-11E/vIL-10 fusion. (A) Schematic representation of the 1-11E/vIL10 fusion protein, as cloned into
the pcDNA expression vectors. SP, signal peptide. The scFv and vIL-10 are separated by an MMP cleavage linker, whereas the His-tag and V5-tag
were incorporated at the C-terminus. (B) SDS-PAGE analysis of purified 1-11E/vIL-10 is shown in the left panel. Purified 1-11E/vIL-10 fusion protein
migrated at approximately 50 kDa, in keeping with the expected molecular weight (~30 kDa scFv plus ~20 kDa vIL-10). Digestion of 1-11E/IL10 by
MMPs is shown in the right panel. 1-11E/vIL-10 fusion protein was incubated with the catalytic domains of MMP-1, MMP-3, and MMP-12 overnight and
analyzed with Western blot by using anti-tetra-His-HRP antibodies. (C) FPLC profile of 1-11E/IL10. The first major peak at approximately 100 kDa
corresponds to the dimer form, and the second minor peak at approximately 50 kDa corresponds to the monomer form.
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penta-His HRP was performed as described [9]. Gel filtra-
tion chromatography was performed by using a HiPrep
16/60 sephacryl S-200 (GE Healthcare, Little Chalfont,
UK) column connected to an AKTA FPLC (GE Health-
care) in sterile 20 mM Tris–HCl, 150 mM NaCl, pH 8.
In vitro bioactivity
Binding of purified fusion proteins to native CII and ROS-
CII was determined by ELISA and Western blotting as de-
scribed [9], with the bound fusion protein detected by
using mouse anti-vIL-10 (R&D Systems, Abingdon, UK)
followed by anti-mouse HRP (Sigma, Dorset, UK). Bio-
activity of vIL-10 in the fusion protein was tested with a
cell-proliferation assay by using mouse MC-9 mast cells
as described [18]. In brief, on day 1, 5 × 104 cells were
treated with fusion proteins (with or without MMP-1 di-
gestion) at concentrations of 1,000 ng/ml, 100 ng/ml, or
10 ng/ml, as well as control recombinant vIL-10 (R&D
Systems, Abingdon UK). On day 4, cell viability was mea-
sured with Cell Titer Glo (Promega, Southampton, UK),
and plates were read in a luminometer (Dynex, Worthing,
UK) as per manufacturer’s instructions.
Cartilage immunohistochemistry
Immunohistochemistry, by using damaged arthritic cartil-
age from several mouse models of arthritis, was performed.
Samples were from C57BL/6 mice with antigen-induced
arthritis (AIA) [20], DBA mice with collagen-induced arth-
ritis (CIA) [19], and C57BL/6 with destabilization of the
medial meniscus (DMM) [21]. All animal procedures werecarried out under Home Office project licenses issued
under the Animals (Scientific Procedures) Act 1986 as
amended, and the institutional Animal Welfare and Ethical
Review Bodies of Queen Mary University of London and
University of Oxford, approved by the licenses from the
Home Office. Immunohistochemistry was also per-
formed by using human OA cartilage obtained from a
patient undergoing prosthetic knee replacement (pro-
vided by Professor C. Montecucco, Fondazione IRCCS
Policlinico S. Matteo, Pavia, Italy). Human OA were
collected after consent, in accordance with institutional
ethics policies and regulations (approved by Fondazione
IRCCS Policlinico San Matteo, Pavia, Italy).
Safranin O staining was performed according to standard
protocols [22]. Cartilage immunostaining was performed
on 5-μm-thick sections, which were deparaffinized, hy-
drated, antigen retrieved, and blocked, as described [9]. Sec-
tions were incubated overnight at 4°C with 1-11E/vIL-10 or
control C7/vIL-10 fusion (10 μg/ml) in DAKO diluent solu-
tion. Binding of the fusion protein was probed by using
mouse anti-vIL-10 (R&D Systems, Abingdon, UK) followed
by 1:1,000 anti-mouse HRP (Sigma, Dorset, UK). DAB
substrate was used as peroxidase substrate (DAKO, Ely,
Cambridgeshire, UK). Sections were counterstained with
hematoxylin and mounted with DPX mount (BDH,
London, UK). Fluorescent immunohistochemistry was also
performed by using Cy5.5-labelled 1-11E/vIL-10 and C7/
vIL-10. Cy5.5 labeling was done according to the manufac-
turer’s instructions (GE Healthcare, Buckinghamshire,
UK). The pericellular matrix was stained by using the rat
anti-heparan sulfate proteoglycan antibody (Millipore,
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anti-rat IgG (Life Technologies, Paisley, UK). Slides were
viewed under the LSM 510 Meta (Zeiss, Cambridge, UK)
using the 488-nm excitation laser to visualize the Alexa-
488 label (green) and the 633-nm excitation laser to
visualize the Cy5.5 label (red).
Mouse models of arthritis
Female C57BL/6 mice of 10 weeks of age were used for
AIA, as described previously [20]. In brief, after initial
immunization with 100 μg mBSA in complete Freud ad-
juvant, inflammation was induced in the knees by
intraarticular injection of 50 μg mBSA in PBS.
CIA was induced as described [19]. In brief, 10-week-old
male DBA/1 mice were immunized by intradermal injection
of an emulsion of 200 μg of bovine type II collagen in 100
μl of Freund complete adjuvant into the base of the tail.
Surgical destabilization of the medial meniscus (DMM)
model of osteoarthritis was performed on 10-week-old
C57BL/6 male mice, as described [23]. In brief, the right
meniscotibial ligament was transected, resulting in the
release of the medial meniscus from its tibial attachment.In vivo localization of 1-11E/vIL-10 in AIA
1-11E/vIL-10 and the control C7/vIL-10 were labeled
with Cy5.5 according to the manufacturer’s instructions
(GE Healthcare, Buckinghamshire, UK), resulting in a
dye-to-protein ratio of 2.2. Before injecting the tagged
fusion protein into mice, its integrity was first assessed
with ELISA and immunohistochemistry, as described
earlier. To track the fusion proteins in vivo after inflam-
mation, 1 μg of Cy5.5-labeled fusion protein was injected
intraperitoneally (i.p.) 1 day after the mBSA re-challenge
in the AIA model. Epifluorescence images were obtained
daily after anesthesia induction with isofluorane in an IVIS
Spectrum imager, by using an excitation wavelength of
675 nm and an emission wavelength of 720 nm (Perkin
Elmer, Waltham, MA, USA). Images were analyzed by
using Living Image 4.4 to obtain the average fluorescence
intensities of a circular region of interest encompassing
the knee joint. Four days after i./p. injection of Cy5.5-la-
beled fusion protein, a single animal was killed and the
knees, liver, kidney, heart, and spleen imaged ex vivo.
The knees were further embedded in optimal-cutting-
temperature media (VWR, Leicestershire, UK), before
freezing in isopentane cooled by liquid nitrogen, before
storage overnight at -80°C. The joints were sectioned at
a thickness of 15 μm by using a Leica CM1900UV cryo-
tome (Leica Biosystems, Milton Keynes, UK). The cryosec-
tions were fixed in ice-cold acetone before being air dried
and blocked in DAKO blocking solution (DAKO, Ely,
Cambridgeshire, UK). Fluorescence confocal microscope
images of the sections were obtained, as described earlier.Treatment of AIA with 1-11E/vIL-10
On days 1 and 3 after the mBSA rechallenge in the AIA
model, animals were injected i.p. with 30 μg of 1-11E/IL10
or C7/vIL-10. Swelling of the knee was measured daily by
using calipers. On day 3, three animals were killed by cer-
vical dislocation, serum was collected, and the knee joints
were dissected and fixed in formalin (2% (vol/vol)) over-
night, decalcified in EDTA for 5 weeks, and embedded in
paraffin. Serial sections 2 μm in thickness were cut and
further stained with safranin O. Serum cytokine con-
centrations were determined by using a seven-plex
mouse pro-inflammatory assay kit (Mesoscale Discov-
ery, Gaithersburg, MD, USA) in triplicate, according to
the manufacturer’s instructions.
Levels of inflammation and redox state were determined
by monitoring the luminescence after i.p. administration
of 100 μl of 50 mg/ml luminol (5-amino-2,3-dihydro-1,4-
phthalazine-dione; Sigma, Dorset, UK) in PBS. Luminol is
a redox-sensitive compound that emits blue luminescence
(λmax 425 nm) when exposed to ROS but depends on
myeloperoxidase activity [17]. The luminescence was de-
termined by analyzing images obtained 15 minutes after
luminol injection in the IVIS Spectrum Bioluminescence
settings.
Safranin O-stained knee sections were scored for disease
as follows: 0, Control; 1, no subsynovial inflammation, syn-
ovial healthy chondrocytes; 2, some evidence of soft-tissue
edema and subsynovial inflammation, some zones of
partial-thickness loss of cartilage staining; 3, marrow in-
volvement becoming apparent, frank soft-tissue edema,
moderate inflammation with synovial thickening, inflam-
matory tissue encroaching into joint, nonadhered. Cartilage
matrix depletion evident; no chondrocyte death; 4, Edema
of soft tissue, subsynovial inflammation, pannus encroach-
ment and adhesion to cartilage, full-thickness cartilage
staining depletion, chondrocyte clumping and death, and
inflamed marrow.
Statistical analysis
Statistical analyses were undertaken by using Prism
(Graphpad, La Jolla, CA, USA) by using Newman-Keuls
multiple-comparisons test. An α value of 0.05 was used
as the threshold for significance.
Results
Biochemical analysis of fusion proteins
A schematic representation of 1-11E/vIL-10 fusion proteins
is shown in Figure 1A. In SDS-PAGE analysis, purified 1-
11E/vIL-10 fusion proteins migrated at approximately 50
kDa, in keeping with the expected molecular weight (~30
kDa scFv plus ~20 kDa IL-10, Figure 1B, left panel). When
fusion proteins were incubated with MMP-1 or MMP-12,
the C-terminal vIL-10 (~20 kDa) product was observed as
a result of MMP-1 and MMP-12 cleavage but not with
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the 1-11E/vIL-10 fusion in solution was further demon-
strated by gel-filtration chromatography, showing a major
peak at 100 kDa, corresponding to the fusion protein dimer,
anticipated as native IL-10 forms dimers. A smaller peak
around 50 kDa corresponding to the fusion-protein mono-
mer was also observed (Figure 1C).
In vitro bioassay of 1-11E/vIL-10 fusion
The antigen specificity of 1-11E/vIL-10 fusion proteins
was determined with ELISA, by using native CII (NT CII),
ROS-CII (CII modified by glycation (GLY) and HOCl
(HOCl)), or control HEL as target antigens. 1-11E/vIL-10
had increased binding to both GLY and HOCl-derived
ROS-CII (as previously demonstrated for 1-11E scFv [9])
and not to HEL (Figure 2A). Conversely, the C7/vIL-10 fu-
sion protein was specific to HEL (Figure 2A).
The specificity of the 1-11E/vIL-10 fusion to ROS-CII
was further confirmed with Western blot. 1-11E/vIL-10
bound to all forms of CII, but not to HEL (Figure 2B).
Binding pattern included binding to a range of CII frag-
ments in the region of 25 to 100 kDa; and high-
molecular-weight aggregates (higher than 250 kDa). In
addition, 1-11E/vIL-10 bound to the electrophoretic
band that corresponds to the intact native CII-chain
polypeptide, although in ELISA, 1-11E/vIL-10 did not
bind to native CII (Figure 2B).
The bioactivity of vIL-10 in the fusion protein was tested
by its effect on MC-9 cell proliferation. Different concen-
trations (1,000, 100, and 10 ng/ml) of 1-11E/vIL-10 fusion
proteins and C7/vIL-10 stimulated weak cell growth, but
proliferation was increased (P < 0.01) up to comparable
levels with commercial recombinant IL-10 after digestionEL
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Binding of damaged arthritic cartilage by
1-11E/vIL-10 fusion
We tested the binding specificity of 1-11E/vIL-10 to ROS-
CII within the cartilage matrix of arthritic damaged cartil-
age from all three mouse models of arthritis (AIA, CIA,
and DMM) and human OA cartilage by immunohisto-
chemistry (Figure 3). In AIA cartilage, a diffuse and strong
pattern of staining with 1-11E/vIL-10 of the artificial zone
was observed. No staining was seen with C7/vIL-10. A
similar pattern of staining was seen for CIA cartilage. The
staining of DMM cartilage was more diffuse, and we ob-
served staining in all zones (superficial, middle, and deep
zone). No background staining was seen for control C7/
vIL-10 (Figure 3A). No staining of healthy mouse cartilage
was observed (data not shown). Human OA cartilage dis-
played a diffuse pattern of staining as a territorial “halo”
around the chondrocyte with 1-11E/vIL-10 and with very
strong staining in extensive eroded areas as a reflection of
high levels of ROS-CII in these areas (Figure 3B). Very
low background staining with C7/vIL-10 was seen in hu-
man cartilage around the chondrocytes.
In vivo localization of 1-11E/vIL-10 fusion to inflamed
tissue in AIA
The targeting function of the 1-11E portion of the fusion
protein to inflamed tissue was addressed by tagging the fu-
sion protein with the Cy5.5 fluorophore and injecting i.p.
into animals with AIA. Subsequent in vivo fluorescence
imaging indicated that the 1-11E/vIL-10 fusion proteinvIL
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the contralateral uninflamed joint and the control C7/vIL-
10 fusion protein (representative images taken 3 days after
i.p. injection shown in Figure 4A).
Quantification of the average fluorescence within a circu-
lar region of interest encompassing the knee joint indicated
that the maximum amount of 1-11E/vIL-10 fusion protein
tracking to the inflamed joint occurred 3 days after i.p. in-
jection (Figure 4B; P < 0.0001). Ex vivo fluorescence im-
aging of the internal organs 4 days after i.p. injection
indicated no difference in the clearance of 1-11E/vIL-10
and C7/vIL-10 (Figure 4C), demonstrated by strongflorescence seen in the kidney and liver because of clear-
ance. Nevertheless, no signal was seen in the heart and
spleen. Frozen sections of excised knee cartilage indicate
that the Cy5.5-labeled 1-11E/vIL-10 is present throughout
the cartilage of inflamed joints, as well as within some
chondrocytes, but not in the contralateral joint (Figure 4D).
C7/vIL10 did not show staining of the excised cartilage.
Therapeutic efficacy of 1-11E/vIL-10 fusions in mouse
model of arthritis
The therapeutic potency of the fusion proteins was tested
in two consecutive sets of experiments by using the murine
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http://arthritis-research.com/content/16/4/R151AIA arthritis model in C57BL/6 mice. After rechallenge
with mBSA, mice with a similar degree of knee swelling
were selected for treatment. In the first experiment, a small
group of animals (n = 3) was injected i.p. with 30 μg 1-11E/
vIL-10 or control C7/vIL-10 after mBSA rechallenge to de-
termine the ability of 1-11E/vIL-10 treatment to reduce oxi-
dative stress as a result of the inflammation. We measured
the level of oxidants present in the inflamed knee by i.p. in-
jection of luminol. Figure 5A shows that the reduction in
levels of luminescence was accelerated in 1-11E/vIL-10
treated mice compared with mice treated with C7/vIL-10
or nontreated control mice. Hence, the intensity of the
luminol signal in the arthritic knee correlated with ac-
celerated reduction of knee swelling by 1-11E/vIL-10 in
comparison to C7/vIL-10 and control nontreated mice
(Figure 5B, C, p = 0.6317).
To confirm further the efficacy of treatment with 1-11E/
vIL-10, we performed a large experiment using AIA mice
(n = 10-12) injected with 30 μg per injection of the 1-11E/
vIL-10 or control C7/vIL-10 fusion protein at days 1 and 3
after rechallenge with mBSA. Once again, we observed a
significant reduction in knee swelling in 1-11E/vIL-10
treated mice compared with mice treated with C7/vIL-10
or PBS controls (Figure 6A).
Histologic analysis of the excised knee joints from 1-
11E/vIL-10-treated versus C7/vIL-10-treated mice fromday 3 showed a clear difference between the two groups
(Figure 6B). In joints from the nontreated mice, several
pathologic features of a moderate arthritis were observed.
Edema of the soft tissues was noted, with thickening of the
subintima with a vigorous inflammatory infiltrate. En-
croachment of inflammatory pannus from the point of
insertion was found, with a thin layer of inflammatory tis-
sue adhering and overlying the cartilage associated with
roughening. Cartilage was heavily depleted of glycos-
aminoglycan staining, with some islands of new synthe-
sis surrounding chondrocytes. Evidence of chondrocyte
clumping was found, and some lacunae were absent
of chondrocytes. Bone marrow was inflamed, and
subchondral bone depleted and disorganized (Score 4).
The cartilage from healthy control (HC) animals was
smooth, with clear staining with safranin O (Score 0).
Treatment with C7/vIL-10 showed a reduced inflamma-
tory picture compared with nontreated joints. Bone
marrow inflammation was absent, subchondral bone
healthy, and cartilage showed much stronger glucosami-
noglycan staining. However, zones of cartilage glycos-
aminoglycan depletion were still evident. Soft-tissue
edema was reduced, but not to the levels of healthy con-
trol, and some inflammatory infiltrate with synovial lin-
ing layer thickening was observed (Score 2). Treatment
with 1-11E/vIL-10 looked essentially normal. Although
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http://arthritis-research.com/content/16/4/R151some sublining layer inflammatory influx was noted,
very little thickening occurred. The synovial lining layer
looked normal, with no encroachment from the point of
insertion. Cartilage appeared healthy, smooth, and nor-
mal, with staining for glycosaminoglycan equivalent to
that of the healthy control, with no patches of depletion,
as seen in the C-7/IL10-treated joint. Marrow and sub-
chondral bone appeared normal (Score 0). Cytokine
profiles were analyzed in three animals from each group
on day 3 (Figure 6C). Pro-inflammatory cytokines levels
in the 1-11E/vIL-10-treated group were significantly
lower than in the C7/vIL-10 group (P = 0.0175, except
for IFN-γ, which was similar in all groups) and similar
to the levels observed in the healthy control animals.
Discussion
Biological therapies have revolutionized treatment for
RA patients; however, they have various drawbacks due
to incomplete response in 30% to 40% of patients, side
effects, and high cost [24]. Development of novel ap-
proaches to overcome these limitations is becoming
even more important, as recent evidence supports the
advantage of earlier use of TNF-α inhibitors, before the
failure of conventional DMARDs, and especially to use
TNF inhibitors in combination with methotrexate asfirst-line therapy in patients with poor prognosis and signs
for rapidly progressive disease [25]. Our hypothesis is that
targeted therapy may address at least some of these draw-
backs, as it allows concentration of the bioactive mole-
cules within the damaged joints and, thus, increase
potency while minimizing side effects. In addition, tar-
geted therapy may resolve some of the obstacles in achiev-
ing beneficial treatment with anti-inflammatory cytokines,
as opposed to treatment by blockade of pro-inflammatory
cytokines, which has become an established treatment for
RA. Because of the poor pharmacokinetics (~30 minutes
half-life) of anti-inflammatory cytokines, high nontolerable
dosages have been used to achieve efficacy in clinical trials.
In fact, the clinical development of both interferon β
[26,27] and IL-10 [16] was discontinued because of an in-
sufficient efficacy.
Here we describe that vIL-10 fused to the human anti-
body fragment specific for damaged arthritic cartilage is a
valid targeted anti-inflammatory therapy in the treatment
of a mouse model of arthritis.
Although the original anti-ROS-CII specificity of 1-11E
was maintained in 1-11E/vIL-10, the in vitro vIL-10 bio-
activity of 1-11E/vIL-10 and C7/vIL-10 fusion proteins
was very low until they were cleaved by MMP-1, indicat-
ing that vIL-10 was latent before the MMP-1 digestion.
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http://arthritis-research.com/content/16/4/R151Human IL-10 (hIL-10) fused to the scFv was, however, ac-
tive [17,18], raising the very interesting question of the dif-
ference between hIL-10-and vIL-10 as a fusion partner in
terms of therapeutic potential. vIL-10 has been shown to
bind to and signal through human IL-10R1 [28]. The re-
gions on the surfaces of the hIL-10 and vIL-10 that make
contact with the receptor are essentially the same. The
binding affinity of vIL-10 (which has 92% sequence iden-
tity to hIL-10) to cell-surface IL-10R1 is, however, ~1,000-
fold lower than that of hIL-10 [29]. This difference in
receptor-binding affinity is thought to be caused by subtle
changes in the conformation and dynamics of two loop
structures and the interdomain angle [30] as a result of a
single amino acid substitutions at position 87 of isoleucine
to alanine (I87A) in vIL-10 [29]. Similar to vIL-10, I87A
substitution in hIL-10 results in hIL-10 with only im-
munosuppressive, but not immunostimulatory functions.Keravala et al. [14] demonstrated that the I87A mutant re-
sulted in significant improvement of the pathology in the
treated joints to similar levels as the vIL-10, whereas Ding
et al. [31] showed that the I87A mutant induced similar
Stat1, Stat3, and Stat5 activation as hIL-10. The latency of
vIL-10 in our fusion probably reflects the low affinity of
vIL-10 in comparison to hIL-10, where we used 1,000 ng
of 1-11E/vIL-10 and control vIL-10 to see significant
growth effect on the MC-9 cells, whereas 10 ng of hIL-
10 was sufficient [17]. The close proximity of the scFv
probably induced further conformational changes as
well as changes in the dynamics of two loop structures
and the interdomain angle, which has resulted in lack of
binding to the receptor. The fact that 1-11E/vIL-10 is
systemically latent until it is cleaved by MMP in the
arthritic joints is advantageous, as it will be activated
only in inflamed joints where local MMPs, especially
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http://arthritis-research.com/content/16/4/R151MMP-12 in early inflammation [19], cleaves it from the
fusion, with little sequestering of the cytokine by sys-
temic receptors [32].
1-11E/vIL-10 maintained the specific binding to arthritic
cartilage. Hence, the in vivo accumulation of 1-11E/vIL-10
in the inflamed joint showed a dramatic improvement
compared with 1-11E scFv, with sustained targeting for 4
days compared with 2 hours, respectively. Possibly this is
due to the increased molecular weight to 100 kDa for 1-
11E/vIL-10 compared with 30 kDa for 1-11E scFv, and
above the kidney threshold. This also explains why treat-
ment efficacy was maintained for several days. The 1-11E/
vIL-10 fusion greatly accelerated the reduction of knee-
joint swelling, redox state, and levels of pro-inflammatory
cytokines in comparison to control C7/vIL-10. The lack of
therapeutic effect with the C7/vIL-10 could be explained
by the lack of targeting to the arthritic joint, which then
resulted in much lower (suboptimal) local concentration
in the arthritic joints. Interestingly, serum levels of mouse
pro-inflammatory cytokines in the 1-11E/vIL-10-treated
mice were significantly lower compared with C7/vIL-10-
treated mice and almost as in healthy mice. Mouse IL-10
levels in 1-11E/vIL-10-treated mice was, however, a bit
lower than that observed in C7/vIL-10-treated mice, pos-
sibly reflecting the reduced inflammation in the 1-11E/
vIL-10-treated group and thus fewer anti-inflammatory
cytokines were needed to combat the inflammation. These
data, however, must be further confirmed in a larger ex-
perimental setting.
Conclusions
The results from this study demonstrate that anti-inflam-
matory cytokines can be targeted specifically to diseased
arthritic joints with increased efficacy in comparison to
nontargeted treatment. These data demonstrate a further
milestone with potential for further development of opti-
mal treatment of RA, where blockade of pro-inflammatory
cytokines or treatment with anti-inflammatory cytokines
may be used alone, or in combination. Indeed, the testing
of combination biological therapies for RA has largely
been avoided for safety concerns, but targeted therapeutics
may enable this in the future.
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